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Message from the Chair
WHERE IS HEALTHCARE GOING?
The health care sector is undergoing transformative changes as regulations
and the market economy drive performance measures from volume to
value. The failure during the past decade to meaningfully accomplish this
has created a profound appetite for the transformation of health care into
a risk-based value realization economy.
These changing dynamics are creating a realignment of the key
traditional stakeholders:
• Patients			
• Providers			
• Hospital Networks		
• Integrated Health 		
Care Delivery Systems

•
•
•
•

Insurers
Governmental Agencies
Academia
Biotechnology and
Device Manufacturing

And are making way for emerging, non-traditional health care players:
• Informatics Technology Agents
• Financial and Private Equity Sector
All shareholders are converging and trying to capture the value associated
with the new emerging economy. This impending disruption will greatly
alter the status quo, allowing new players into the health care space,
effectively changing the roles of traditional stakeholders. We are witnessing
unprecedented levels of activity as participants are consolidating through
mergers/acquisitions or creating entirely new entities.
What is clear is that this dynamic and shifting market over the next ten
years will not look like it has in the past ten years. What is equally clear is
the considerable opportunity this represents. The market will be further
transformed through disruptive innovation both in technologies and in the
models that deliver them. The “volume to value” continuum is incomplete
and inherently flawed as it has not been possible to effectively quantify
the true definition of value … value itself. This inability to quantitate value

has led to the failures of the past decade to transform health care,
largely because value is an intermediate stop in the actual continuum,
which is volume > value > risk. As is the case in many other industries,
risk in health care can be effectively quantified and measured, and
thereby embody the true meaning of value.

WHO IS AURORA HEALTH CARE?
The State of Wisconsin contains about 5.8 million people with its key
demographics closely mirroring the national representation. For instance,
as of 2014, 14.9% of the WI population is 65+, which is nearly identical to
the national makeup. Aurora Health Care primarily serves the eastern
1/3 of the state by geography, which includes approximately half the
state population including the largest city—Milwaukee.
At the county level or when considering rural vs. urban areas, these
demographics can change significantly. For example, the percentage
of age 65+ in Milwaukee County is only 12.1%, but in Door County it is
26.4%. When designing health care offerings to best serve a particular
population, the expected geographic scope influenced by a given
service and the demographics within that scope should be considered
and adjusted as necessary.
Aurora Health Care System represents a unique entity with a 15-hospital
network and large integrated primary care and specialty service lines
covering an expansive geographic region. A strong foundation has
been built within the health system to include primary practice groups,
numerous physical locations, as well as incredible research infrastructure.
The health system has set its next and foremost requirement to expanding
its network of hands-on quality service providers and specialties through
a tertiary and quaternary clinical focus. Quality is a primary focus for
all, as is maintaining pluralistic model and integrating existing providers
where possible while maintaining this objective. The system has
successfully accomplished this in Cardiac, Women’s health and
Transplant and now is in the process to do the same in Neurosciences.
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Quality and Patient Satisfaction
High-Quality Care for Your Life

How We Deliver Quality

What Makes “High Quality”?

We continually strive to give high-quality care and results.
It is a promise we take very seriously. In order to deliver high
quality, we have a step-by-step approach that is carried out
across our entire organization.

For Aurora, it’s about offering care for your life, not just for
your health. We do this by:
•P
 romoting health care innovation and staying up on the
latest advances
• Setting high goals for ourselves
• Keeping track of our progress as we reach those goals
You have a right to expect high quality wherever you go for
health care. But how do you define it?

Our main approach to delivering high-quality care is Care
Management, which is a coordinated, patient-centered approach
to finding better ways of preventing and treating health problems.
The Care Management approach to quality means that we work
together to:
• Define the health care needs of the people we serve
• Research the best ways to meet those needs

At Aurora Health Care, quality is our pursuit to give our patients
better results than they can get anywhere else. That means we
need to:
• Update our knowledge through continuous research on
“best practices”—that is, how medical and nursing science prove
to be the best possible ways to prevent or treat specific problems
 et goals for ourselves based on medical science and what health
•S
care systems with the best results in the country are doing
• Keep track of our progress and continually set higher goals
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•D
 esign a plan of action that can be carried out by
all of our health professionals
• Measure our results (against national standards)

The foundational architecture of aerospace industry and innovation
continues to provide guidance for the operating room of the future.
Aviation safety experts measure air traffic routes for safety using quality
metrics. Our new software allows us to map millions of previously unseen
white matter tracts in real time, rendering them in a dynamic, threedimensional modeling system. Like air traffic routes, we are now able to
apply principles of aviation safety to the white matter tracts of the brain.
The software allows the surgeon to develop and design a plan that can
be fully processed and ready for execution in less than 15 minutes.
Millions of fibers are now conspicuous and salvageable, and are being
visualized preoperatively.
With this capability, clarity of points is also visualized in order to build an
individualized and adaptable approach for each surgery, entirely dependent
on specific patient anatomy. The dictation of a particular area of entry is
based on what was once believed to be invisible anatomy, namely nerves.
The concrete presence of white matter tracts now gives rise to the notion
that we are obligated to take these visual truths into consideration when in
the operating room. In comparison to many of the systems currently used,
this aeronautics-like approach performs in a rapid and automated manner
with little human input and resources, making this process cost-efficient
and accurate. Only now can individualized surgical plans for each specific
patient be generated and ready for execution.
ANII has been an international leader in this effort, recently presenting a
unique three-dimensional patient-specific atlas of the human white matter.
This foundational effort will force the substrate to create a dynamic
living platform to allow individual, patient-specific planning for surgery.
Explicitly, this means that each patient can have their individual case
planned and simulated just like a flight plan – this is a critical step
towards precision medicine.
The planning of each surgical case begins with precise, detailed, and
advanced imaging. Information is only as good as its quality and reliability.
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The complex imaging data is thoroughly evaluated by a computer
algorithm that determines whether or not it is ideally suited for surgical
planning. If not, the imaging is repeated before the patient leaves the
imaging suite. This front-end quality assessment reduces costs and errors,
but also ensures that as data is entering the iterative learning platforms,
it has been validated as a source of truth. Once the surgical plan is
generated, it is transferred directly to a robotically-operated video optical
telescopic microscope (ROVOT-m) with a built-in navigation system.
Aurora and the team at ANII were the first in the world to deploy this
integrated system for direct patient care.
This system represents a single, integrated intraoperative solution to
allow surgeons to accurately reach their target while protecting the
eloquent white matter. The plan is displayed onto a high-definition
monitor and merged with multi-modality imaging confirming alignment
for a precise trajectory in order to develop an individualized corridor of
entry for each patient. The harmonious integration of patient-specific,
target-centric planning with enhanced surgical visualization is grounded
on the primary effort to preserve every segment of brain matter as much
as possible, effectively reducing patient morbidity.
The ANII care delivery model is equally unique and innovative as the
technology. In order to reduce the risk and improve outcomes, the
previous principles of scope constraint and patient focus are strictly
adhered. The system is designed so the neuro radiologists (navigators)
design the flight plans in the OR (on the runways) and are actually
present during the critical portion of the procedure to provide input
when needed. In addition, every effort is made to ensure that two
experienced surgeons (pilot & co-pilot) are performing the key portions
of the procedure together, whenever possible. Very few commercial
flights operate with just one pilot to avoid errors and maximize quality
assurance; we are committed to patient safety in the same manner. This
has led to creating innovative models that overcome financial barriers.

Aurora neurosurgeons are now able to see the “flight plan” on this
imaging platform to prepare themselves to navigate the complex
anatomy of each individual patient in advance. They are able to take off
and fly through the surgical space with autopilot functionality as well as
have the freedom to adjust the plan while in flight if obstacles arise and
if deviation is necessary. Information is being acquired in an intelligent,
user-friendly manner with ability to record, capture, and share in real-time,
giving rise to an iterative loop. This analytic execution subsequently gives
the surgeon the advantage of transitioning from a principal technician to
defining diagnoses and future therapeutics. The system feeds this captured
data into an informatics platform that will allow for augmented information
to yield a predictive knowledge for the delivery of precision medicine.
This robotically-guided optics platform is a unique exoscopic system
that offers superior visualization—particularly in the depth of field—in
comparison to existing surgical microscopes, allowing more of the image
to be in focus and usable to the surgeon. The integration of this system
allows for two surgeons—a pilot and copilot—to work simultaneously and
collaboratively with exactly the same view in focus. This also nets an
immersive view for all participants in the OR where the enriched view
yields a full volume that is based on a specific and optimal payload.
The hands-free positioning capabilities track the surgeons’ tools and
thereby increase their surgical efficiency, allowing them to focus on the
surgery at hand rather than continuously adjusting the technology.

RESEARCH ADVANCEMENTS
The next phase of this multi-disciplinary collaboration focuses at the
cellular level through next generation imaging that allows for advanced
interrogation of the brain tissue and the capturing of this within the
informatics system. It is the hope of our surgeons that through the
marriage of technology and innovation with informatics, a movement in
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neuroscience towards precision-based cell therapy including regenerative
stem cell therapies will arise. The story of a cell will follow it through the
entire system from the OR to the bench and back. We are already seeing
the added value in trying to understand the variability in how a patient
responds to a particular therapy based on individual genetic makeup.
The biology of a given tumor varies, as does the biology of a patient.
At ANII, we have invested as extensively in our basic science cell
regenerative laboratories as we have in our clinical efforts. The laboratory
consists of 3 teams of senior PhD scientists, post-docs, and technicians.
The imaging facilities include a specifically-built MRI, representing the
only one in the world currently of its kind. The team has carefully procured
and harvested a unique collection of stem cells from patients’ tumors.
Cells are harvested from patients, grown and implanted into in vivo
models creating the ability to interrogate the tumors in an unprecedented
manner. With the use of ultra-high definition imaging to visualize
and capture the structural organization and chemistry of the tumor
cells, novel treatment protocols can be developed.
Cellular imaging, along with the operative note fully integrated into
one digital record and location of the cell-harvesting, is projected and
recorded in an overall sphere of informatics. This information is
leveraged with technology and imaging to create an interface that
detects and tracks individual patient patterns spanning from preoperative
imaging to the cellular level of the tumor. Ultimately, this phenomenon
will allow for the implementation of real change to be achieved, offering
significant improvements in patient health, the care continuum, and
operating efficacy. This allows for precision, adaptive treatment
protocols for each patient. Several key findings have recently been
reported from ANII regenerative cell laboratories to further the
understanding of brain cancer.

Complex access and treatment algorithms have been developed to
ensure that all patients, primary and metastatic, are reviewed and
considered by the Neuro-Oncology tumor conference team with
comprehensive development of care plans. Through innovative
approaches to care, the management of brain tumors at Aurora
Health Care has evolved beyond just length of life, and has become
fully invested in a patient’s quality of life. We offer the best of the
proven current treatment available today, while bringing the next
generation of innovative chemo and surgical treatment applications
to our commitment to precision medicine with innovative techniques
that adapt to the individual patient.

EXPANDED ENDONASAL APPROACH (EEA)
Revolutionizing the way brain surgeons access
the skull base and upper cervical spine in a
less invasive way.
During endoscopic endonasal surgery, a neurosurgeon and an
otolaryngologist work together to enter the skull base through
the nose. This minimally invasive technique eliminates the need
for external incisions and brain retraction. By removing the back
half of the nasal septum and the bone in front of the sphenoid
sinus, surgeons can reach the skull base.
Tumors are then removed with the help of high-definition optics
and an endoscope. Finally, the skull base is reconstructed using
a flap of the septal membrane—which seals off the brain from
the nose—helping prevent complications.
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The Expanded Endonasal Approach allows access to skull base
tumors minimizing the complications that can be seen with open
skull base surgery, which include infections associated with large
scalp incisions and the side effects seen with brain retraction.
Many patients undergoing EEA spend only one to two days in the hospital,
and recovery time at home can be much shorter than for open skull
base surgery. In addition, there are many scenarios in which EEA causes
less disruption of critical nerves during skull base surgery.
The Expanded Endonasal Approach is used to perform minimally
invasive brain surgery for these conditions:
• Brain tumors
• Cancers of the sinus (squamous cell, sphenoid sinus
carcinomas, adenocystic and metastatic)
• Meningiomas of the skull base
• Pituitary tumors (including pituitary adenomas, acromegaly,
prolactinomas and pituitary apoplexy)
• Olfactory neuroblastomas
• Rathke’s cleft cysts
• Skull base tumors and cysts
• Chordomas and chondrosarcomas
• Orbital tumors and Graves’ disease

MINIMALLY INVASIVE NEUROSURGICAL TECHNIQUES

High-Definition Optics

Deep brain tumors (subcortical), areas of bleeding, and cysts that
were once considered too risky to operate on by many are now often
removed through a precise and patient-specific corridor with our
unique, integrated surgical techniques. This minimally invasive technique
offers patients hope for better surgical results, as well as improved
long-term health outcomes. It also allows our patients to reach the goal
of zero footprint, or no long-term complications as a result of their
tumor or surgery.

This technology allows neurosurgeons to differentiate tissue types with
unprecedented clarity from above the surgical site. Being able to separate
diseased tissue from healthy tissue makes it possible to successfully
remove what would otherwise be considered inaccessible brain tumors,
cysts or other growths difficult to see.

Mapping
An invaluable tool for Aurora’s neurosurgeons, brain mapping depicts
aspects of a tumor and surrounding healthy tissue with enhanced clarity
rendered in a three-dimensional space. This imaging technology allows
surgeons to preplan a patient-specific, real-time surgical pathway before
a brain surgery procedure even begins—which translates into improved
outcomes in the operating room and a faster recovery.
Dynamic Navigation
Neurosurgeons use a GPS-like system that gives them real-time
guidance deep within the brain. Patients can see their brain tumor
removal on the same computer screen that their surgeons use to
track the movements of their surgical instruments.
Safe Access
We use a specialized and innovative tool that minimizes damage
to surrounding tissue by allowing neurosurgeons to safely displace
the natural folds of the brain as they advance to the target site.
This is a critical component of a minimally invasive treatment for
brain tumors and other deep-seated neurological disorders.

Automated Resection
Using a tool about the size of a pencil, neurosurgeons are able to
remove tissue without injury to adjacent healthy brain matter. This
technique is another reason Aurora can offer treatment options
for conditions, such as brain tumors, that were previously deemed
too risky by many.
Directed Therapy Options
Neurosurgeons collect and preserve the brain tissue they remove in
a sterile, closed-capture device for pathology, molecular and genetic
evaluation. These samples provide opportunities to develop
personalized treatment regimens for every patient. This is a critical
step in advancing treatment paradigms. The ability to capture, grow,
and implant the tumor tissue into mice enables the team to study and
develop new targets for treatment that are brought directly back to
the patient in an individualized manner, epitomizing our commitment
to precision medicine.
All of this patient and correlated cell data is then compiled into a
novel image-driven data capture system with the goal of developing
predicted informatics power. Aurora was the first institution in the world
to install and implement this specific image-driven informatics system.
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BRAIN MAPPING
Advanced brain mapping technology lets our team
of experts see the precise location of individual brain
functions—speech, memory and movement—in order
to help determine the most appropriate treatment.
Brain mapping is a critical tool used by neuroscientists to diagnose
long-term, chronic conditions, like Parkinson’s disease; it is also used
to plan surgeries for more acute conditions, such as brain tumors.
If surgery is needed, brain imaging technology may be used before
and during a procedure to differentiate healthy brain matter
from diseased tissue. It can also be used to define a surgical or
navigational strategy to help avoid injury to portions of the brain
needed for critical functions.
Diffusion tensor imaging with white matter tractography is one type of
brain mapping. It uses state-of-the-art technology to create a 3D map
of the brain, which shows the location of nerve fibers that control speech,
memory, cognition, and thought—all of the things that make you … you!
It provides advanced assistance with:
• Determining the best surgical approach to remove a tumor
• Diagnosing and treating a traumatic brain injury
• Finding breaks in brain fibers that may cause the loss of certain
body/memory functions
• Understanding which brain connections are intact and which
are damaged

 ther types of brain imaging technology that works like a GPS system
•O
during surgery, giving neurosurgeons real-time guidance deep within
the brain
Brain mapping is a fundamental element of our minimally invasive
methodology for treating subcortical tumors and cysts that were often
considered otherwise inaccessible.

Aurora has performed more optical robotic
brain surgery than anyone in the world to
date, and ANII was the first in the world to
deploy a unique 3-D brain mapping
platform for patient care.
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Data

Inpatient

Seizures and
Epilepsy

734
6,581

Headaches and
Migraines

5,744

Degenerative
Disorders

990

Multiple Sclerosis

527

241

373

10,927

Stroke/TIA

2,058
9,760

Peripheral
Nerve Disorders
Concussion

242
9,355
188
2,492

Alzheimer’s and
Cognitive Disorders
Hydrocephalus

123
515
114
475
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Outpatient

There are between an estimated 1.6 and

3.8 million sports-related concussions
in the U.S. every year, leading the CDC to
conclude that sports concussions have
reached an epidemic level.
Aurora takes concussion care seriously and has been a proven leader
in concussion assessment, treatment, education and prevention. Aurora
is the top employer of athletic trainers in the state of Wisconsin. By
providing these front-line prevention resources, Aurora’s athletic trainers
ensure baseline tests are administered properly, contact techniques are
being safely instructed, and student athletes and parents are appropriately
educated to assure that all safeguard elements are in place for all
high-risk activities.
In the event of a head injury, athletic trainers have certification and
state licensure that assures evidence-based practice of proper concussion
management. Over 70 Aurora athletic trainers across the state provide
on-field assessment using researched protocols and follow the National
Athletic Trainers Association position statement on management of sport
concussion. Aurora’s athletic trainers work with a complete team of
dedicated health professionals, including pediatricians, orthopedic
surgeons, neuropsychologists, neurologists, family practice physicians,
and physical therapists to reassure proper return to play.

EPILEPSY MONITORING UNIT

LEVEL 4 EPILEPSY CENTER

Patients whose seizures can’t be controlled with medications and those
who may be candidates for epilepsy surgery are often scheduled for
long-term epilepsy monitoring in one of our Epilepsy Monitoring Units.

The Aurora Center for Epilepsy and Neurology has been accredited
as a Level 4 epilepsy center by the National Association of Epilepsy
Centers. Level 4 is the highest level of certification that a program
can receive and ensures it has capabilities in the following:

Information from the study is used to determine if surgery is a
viable treatment or if other options should be considered. This
information helps to do the following:
•E
 stablish an epilepsy diagnosis. In
most epilepsy centers, about 1 in 4
patients who have seizure-like
events do not have epilepsy
• Identify the seizure type. Some
seizure medications are designed
to treat certain types of seizures
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EMU admissions

•L
 ocate the source. Monitoring can
help identify the brain area where
your seizures begin. Lateralization and localization (finding the side
and area) of your seizures is a critical first step in planning any epilepsy
surgery. Seizures are videotaped because your behavior during seizures
can also help to locate the source
•D
 etermine seizure frequency. Video EEG monitoring can identify how
often you are having seizures. Frequently patients have seizures and
don’t know unless someone tells them
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•B
 asic range of medical, neuropsychological, and psychosocial
services needed to treat patients with refractory epilepsy
•N
 oninvasive evaluation for
epilepsy surgery, straightforward resective epilepsy
surgery, and implantation of
the vagus nerve stimulator
•C
 omplex forms of intensive
neurodiagnostics monitoring, as well as more extensive medical,
neuropsychological, and psychosocial treatment
 ffer complete evaluation for epilepsy surgery and a broad range
•O
of surgical procedures, including intracranial electrodes

EASY STREET
Easy Street is a one-of-a-kind environment and facility that provides
a variety of real world experiences to aid in the recovery of our patients,
specifically those suffering from neurological and movement disorders.
This facility includes a grocery store, barber shop, movie theater, bus,
driving range and apartments so our patients have a unique opportunity
to be challenged both mentally and physically over curbs, ramps, and
uneven surfaces before they face those obstacles in the communities
we serve. Easy Street allows for a truly multidisciplinary approach to
care by creating an environment where physician, therapist, and other
medical professionals come together to focus on one priority, helping your
patient regain their highest functional level and re-enter the community.

PARKINSON’S SUPPORT

“You all made a difficult time easier for
me. I came away with a better attitude
and more hope.”
-Jerry D., Big and Loud program participant

Mobile and Fit Parkinson’s Class
This exercise class is designed so that people with Parkinson’s disease
can get better and stay better through exercise. The class targets
movement deficits caused by Parkinson’s disease with the goal of
reducing falls, improving function, and improving quality of life.

LSVT Big and Loud Clinic®
For People Living with Parkinson’s Disease

Health Counseling
Many patients experience anxiety and depression after their diagnosis.
Specialized therapy sessions can help them learn to cope with the
emotional changes.

• Evidence-based exercise program that follows an intensive and
specific protocol to provide maximal results

RESEARCH

• Specialized treatment from certified therapists for Parkinson’s disease
• This treatment has been linked with better outcomes compared to
traditional therapy
• Patients learn how to move BIG and speak LOUD on a consistent basis
• Recalibrates the senses for automatic use of normal
movement and voice

Aurora Health Care is linked to the Parkinson’s Research Institute,
one of only a few organizations with a sufficient database to research
the causes of Parkinson’s disease.
At any given time, the Aurora Health Care Regional Parkinson’s Care
Center and the Parkinson’s Research Institute are involved with a number
of studies evaluating the effectiveness of drugs and treatment methods
not yet available to the general public. At Aurora, patients have access
to the latest in Parkinson’s research and treatment options.

• Uses high effort and intensive treatment to improve everyday function
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Coupled with an extensive team of stroke, cerebrovascular,
endovascular, and critical care neurologists, stroke patients at
Aurora are cared for by the highest level of medical
professionals available.

• Coordination of post-discharge patient self-care based on
recommendations of the Brain Attack Coalition and guidelines
published by the American Heart Association/American Stroke
Association or equivalent guidelines

STROKE CERTIFICATION

•S
 treamlined flow of patient information while protecting patient
rights, security and privacy
• Collection of the hospital’s stroke treatment performance data

Meeting higher standards to support better
outcomes for stroke care
Primary Stroke Certification
Primary Stroke Certification recognizes hospitals for going above and
beyond the standard of care to ensure ischemic stroke patients receive
the highest level of treatment options and quality measures. In
accordance with standards set by the American Stroke Association
and other governing bodies, in order to achieve this certification,
hospitals must meet eligibility standards that include the following:
• A dedicated stroke-focused program
• Staffing by qualified medical professionals trained in stroke care
• Individualized care to meet stroke patients’ needs
• Patient involvement in their hospital care

• Hospital team performance data
• Use of data to assess and continually improve quality of care
for stroke patients
Comprehensive Stroke Certification
In addition to this, some hospitals may also qualify for Comprehensive
Stroke Certification, which meets all of the primary requirements,
as well as sets the highest standards for the care of hemorrhagic
patients and the most complex stroke patients eligible for surgical or
endovascular intervention. Comprehensive eligibility standards
include the following:
 vailability of advanced imaging techniques, including MRI/MRA,
•A
CTA, DSA and TCD
• Availability of personnel trained in vascular neurology, neurosurgery
and endovascular procedures
• 24/7 availability of personnel, imaging, operating room and
endovascular facilities
• ICU/neuroscience ICU facilities and capabilities
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•E
 xperience and expertise treating patients with large ischemic strokes,
intracerebral hemorrhage and subarachnoid hemorrhage
According to the Joint Commission, the governing body currently certifying
the Primary and Comprehensive Stroke Centers at Aurora Health Care, the
benefits of certification reach far beyond the accolades of the accomplishment.
Certification signifies that our organization has established a consistent
approach to stroke care, reducing the risk of error, and has maintained a
consistently high level of quality using effective data-driven performance
improvement.
Get With the Guidelines
Aurora Health Care is proud to be a participating member in the American Heart
Association’s (AHA) Get With The Guidelines® (GWTG) program, an in-hospital
database that promotes consistent adherence to the latest scientific treatment
guidelines for stroke. Participation with GWTG allows our stroke care teams to
have constant access to the most up-to-date research and scientific publication,
gives us a competitive advantage in the healthcare marketplace, and provides
performance feedback reporting for continuous quality improvement.
Target Stroke Awards
•T
 arget: Stroke Honor Roll: Time to therapy within 60 minutes in 50% or
more of acute ischemic stroke patients treated with IV tPA
•T
 arget: Stroke Honor Roll–Elite: Time to therapy within 60 minutes in
75% or more of acute ischemic stroke patients treated with IV tPA
•T
 arget: Stroke Honor Roll–Elite Plus: Time to therapy within 60 minutes
in 75% or more of acute ischemic stroke patients treated with IV tPA &
DTN, within 45 minutes in 50% of acute ischemic stroke patients treated
with IV tPA
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STK-1: VTE
Prophylaxis

STK-2:
Antithrombotics at
Discharge

STK-3:
Anticoagulation at
Discharge

STK-4:
IV tPA
Administration

STK-5:
Antithrombotics
Day 2

STK-6:
Statin on
Discharge

COMPREHENSIVE CORE MEASURES COMPLIANCE:

STK-8:
Stroke
Education

99.3%

99.9%

95.7%

98.0%

97.9%

99.7%

AHC vs. WI Hospitals

99.5%

99.4%

91.0%

98.3%

98.0%

97.8%

99.4%

99.6%

97.9%

100%
99%
98%
97%
96%
95%
94%
93%
92%
91%
90%

99.8%

PRIMARY CORE MEASURES COMPLIANCE:

STK-10:
Assessed for
Rehabilitation

AHC vs. All CSC

100%
90%
80%

CSTK-1:
NIHSS
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CSTK-2:
mRS at
90 days

CSTK-3:
Severity
Measurement
SAH/ICH

CSTK-4:
Reversal
Initiation ICH

CSTK-5:
No Hemorrhagic
Transformation

CSTK-6:
Nimodipine
Administered

CSTK-7:
Median Time to
Revascularization

79.1%

69.6%

121 minutes

74.1%

100%

93.1%

96.6%

88.4%

100%

48.1%

90.1%

86.4%

98.0%

40%

74.1%

50%

92.7%

60%

118 minutes

70%

CSTK-8: TICI
Post-Treatment
Grade

Aurora St. Luke’s
Southshore is

1 of only 3

Primary Stroke Centers:
Aurora BayCare Medical Center			

GOLD PLUS

Aurora Medical Center Manitowoc County		

GOLD PLUS

Aurora Medical Center Oshkosh			

GOLD PLUS

hospitals in the entire
state of WI to win an
Elite Plus stroke
quality award.

Aurora Sheboygan Memorial Medical Center	GOLD PLUS,
TARGET Stroke
Honor Roll–Elite
Aurora Medical Center Summit			

GOLD PLUS

Aurora Medical Center Grafton			

GOLD PLUS

Aurora St. Luke’s South Shore			SILVER PLUS,
TARGET: Stroke
Honor Roll–Elite Plus
Aurora Sinai Medical Center				

GOLD PLUS

Aurora West Allis Medical Center			

SILVER PLUS

Aurora Memorial Hospital of Burlington		

GOLD PLUS

Aurora Medical Center Kenosha			

SILVER PLUS

Aurora Lakeland Medical Center			

GOLD PLUS

Of the 40 certified stroke centers in the
state of Wisconsin, Aurora Health Care
locations are 13 of them, representing

almost 33% of the entire state.

Comprehensive Stroke Centers:
Aurora St. Luke’s Medical Center			GOLD PLUS,
TARGET Stroke
Honor Roll–Elite
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AURORA BACK AND SPINE PROGRAM

In most cases, back pain can be managed
conservatively and without surgery. The Aurora
Back and Spine program provides treatments
that will help provide a solution to back pain
and get patients back to an active life.
With one call you’ll be connected to our team of experts led by
a spine nurse navigator that guides patients through every step
of the diagnosis and treatment process.

Data
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Aurora Back and Spine is part of an integrated health system that treats
not just the spine, but the patient as a whole person. Combining medical
history, lifestyle, and patient desire, we seek treatment options that work
best for each individual patient.
Treatment options might include the following:
• Physical therapy		

• Behavioral health

• Orthopedics			

• Neurosurgery

• Pain management		

• Integrative therapy

• Chiropractic

SPINE CERTIFICATION
Inpatient

Outpatient

Meeting higher standards to support better
outcomes for spine care

Spinal Tumor

25

22

Spine Fracture

493

5,867

Cauda Equina

7

31

Stenosis/Spondylosis

1520

11,982

Disc Degeneration

2134

12,465

Back Pain

270

14,258

Aurora performed more optical robotic

Nerve Disorders

176

10,912

Other Spine

17

1,424

spine surgeries in 2015 than anyone

Joint Commission Spine Center Certification confirms that a spinal surgery
program is in compliance with consensus-based national standards; has
an effective and consistent use of appropriate, evidence-based clinical
practice guidelines for the discectomy, laminectomy, and spinal fusion
patient populations; and performs collection and analysis of spinal-specific
performance measures. Aurora Sheboygan Memorial Medical Center has
earned this distinction for their outstanding care of spine patients.

else in the world.
		

BCBS BLUE DISTINCTION®

Evaluating what matters
Blue Distinction Center designations are awarded to health care facilities
based on a thorough, objective evaluation of their performance in the
areas that matter the most—quality care, treatment expertise and overall
patient results, just to name a few. The criteria are established with the
help of expert physicians and medical organizations. Blue Distinction
Centers have a proven history of delivering better quality and results
than health care facilities without these recognitions.
Blue Distinction Centers for Spine Surgery provide comprehensive
inpatient spine surgery services, including discectomy, fusion and
decompression procedures. Research confirms that designated
health care facilities in this area have lower readmission rates and
fewer reoperations than nondesignated facilities.
BCBS Blue Distinction Centers:

Aurora
BayCare
Medical
Center

Aurora
Medical
Center
Grafton

Aurora
St. Luke’s
Medical
Center
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A Team Approach

Aurora Health Care’s neuroscience rehabilitation
team provides some of the most advanced rehab
care possible through a team approach to medical
services and physical, occupational, speech,
recreational and psychological therapies.
THE AURORA DIFFERENCE
• Private rooms, a rehab gym, an apartment that simulates the
home environment, access to a healing garden and much more

Restoring independence
The goal of neuro rehab is to help restore activities of daily living—
mobility, strength, balance, swallowing, speech, memory, thinking,
coping, etc.—so that patients can remain active and independent.
The Aurora inpatient rehab team measures improvement using a tool
called the Functional Independence Measure. This tells how much help is
needed with things such as eating, grooming, bathing, dressing, using a
toilet, walking, using a wheelchair, getting in and out of chairs, using stairs,
talking and thinking skills. On admission, patients usually need a lot of help
to complete a task. At the time of discharge, nearly 100 percent of our
patients show improvement on the Functional Independence Measure.

• Advanced rehab technology, such as Bioness NESS and LiteGait
mobility devices, Nintendo Wii systems, Kay Digital Swallowing
Workstation and Video Stroboscopy System, VitalStim, and
interactive metronome, acupuncture, Dynavox
• State-of-the-art facilities accredited by The Joint Commission.
• Functional EASY STREET Environment®
• Accredited by the Commission on Accreditation of Rehabilitation
Facilities (CARF), including a specialty accreditation in stroke
rehabilitation. CARF accreditation is the “gold standard” for
rehab programs
• One of 18 hospital systems in the U.S. with four-time Magnet
designation, demonstrating the highest level of excellence
in nursing care, quality and patient satisfaction
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OUTPATIENT NEURO REHAB
Provides exceptional therapy services for people
who live at home and have experienced physical
limitations caused by stroke, neurological
disorders, or other reasons
The outpatient neuro rehab program is backed by an experienced
team of professionals from the following areas:
• Occupational Therapy		

• Physiatry

• Physical Therapy		

• Psychology

• Speech Pathology		

• Therapeutic Recreation

• Nursing and Social Work

• Integrative Medicine

While in our care, the team meets on a regular basis to discuss the
patient’s progress and treatment plans. We communicate with the
patient and their family and/or home caregivers along the way.
The outpatient neuro rehab program is different from traditional
outpatient therapy because it is designed to provide treatment by
several experts located all in one area. Sessions are scheduled to
meet the individual needs of each patient. Sessions may be more
frequent at first and then lessen. This spreads the sessions over
a longer period of time for greater benefit. When appropriate, a
patient may benefit from rest breaks, time for meals, or time to
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practice a home program with supervision in the clinic, but outside
the one-on-one therapy session. We are also able to provide
aquatic therapy using an off-site swimming pool. A recreation
specialist is available to help patients recover skills for the things
they enjoy doing during their free time.
Individualized treatment
Our team of rehab specialists assesses a patient’s needs to create
a treatment plan that’s right for them. Individualized patient goals
are established using a team approach to do the following:
• Assist the patient and family with adjusting to a new lifestyle
• Challenge people to reach their best physical, emotional, speech,
social and community potential
• Educate each person and their family about therapy and what
each member of the team does
• Maintain or improve each patient’s level of independence after
treatment through community resources

Comprehensive care provided
The comprehensive treatment program consists of sessions
that emphasize the following:
• Balance		
• Safety

In addition to our comprehensive outpatient neuro programs
Aurora Health Care offers neuro rehab across eastern Wisconsin.
This includes a connected network of over 30 clinics with
therapy experts dedicated to neuro rehab.

COGNITIVE REHABILITATION AND
ACTIVITIES PROGRAM

• Fine motor skills
• Home program instruction
• Communication and cognition (such as speaking,
problem solving and memory)
•F
 unctional mobility and transfer training, including gait training
(walking and getting around at home and in the community)
• Self-care abilities & home management
Other areas of treatment may include the following:
• Aquatics		
• Community reintegration and leisure skills
• Driving skills through our driver assessment program
• Low vision/visual-perceptual skills
• Swallow therapy (including electrical stimulation)
• Vestibular rehabilitation

A therapy-based, multidisciplinary assessment and
treatment program designed for patients in the
early stages of dementia or cognitive decline
The Cognitive Activities Program, provided by occupational and
speech therapies in an outpatient setting, is focused on adapting
strategies, compensatory methods and restorative therapies the
individual and/or family members can use in the client’s
home environment.
Patients are assessed for motor functioning, visual perception and acuity,
performance of IADL (activities of daily living), memory, medication
management, financial management, language and social interaction.
Cognitive skills, such as attention, memory, executive functioning,
problem solving, organization and sequencing are also explored as
part of the evaluation and treatment process.

• Gender-specific therapy for bladder/bowel incontinence
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The goal of the Cognitive Activities Program is to facilitate and maintain
the highest possible level of independence for individuals and continued
success in their home environments, as well as to provide the client, their
family and caregivers the tools needed to achieve the following:
• Education about cognitive weaknesses and strengths to build awareness
• Development of skills through enhancing attention
• Use of internal and external compensatory strategies
• Application to everyday life via functional activities training
Speech therapy will focus on memory, language, social interaction,
reasoning and problem solving. Occupational therapy will focus on
visual perception, acuity, activities of daily living, medication
management, financial management, home safety and cognitive skills
related to driving.

LSVT BIG AND LOUD®
LSVT Big and Loud Clinic is specialized treatment from certified
therapists for Parkinson’s disease. This treatment has been linked to
better outcomes compared to traditional therapy.
Through the LSVT Big and Loud® Clinic, patients are taught the following:
• How to move “BIG” and speak “LOUD” on a consistent basis
•H
 ow to recalibrate their senses for automatic use of normal movement
and voice
• How to use high effort and intensive treatment to improve
everyday function
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LOW VISION PROGRAM
The Low Vision Rehabilitation Program provides comprehensive
treatments from therapists specializing in treatment to assist persons
with low vision due to eye diseases (diabetic retinopathy, macular
degeneration, cataracts, glaucoma) or acquired/traumatic brain injury
(diplopia, visual field cut, visual inattention). Our goal is to help patients
use their remaining usable vision and learn strategies to compensate
for visual loss during daily activities.

VESTIBULAR AND BALANCE REHAB
Aurora Rehabilitation Center’s Balance and Vestibular Program is
recognized as a regional leader in the rehabilitation of balance and
vestibular disorders. Our physical therapists have extensive training
and experience in this specialty. The interdisciplinary team approach
to rehabilitation involves close communication between the physical
therapist and the patient’s PCP, an otolaryngologist, and other
specialists as needed.
The SMART Balance Master® system is part of Aurora Rehabilitation
Center’s comprehensive balance program, treating patients with
impaired balance related to conditions including vertigo/dizziness,
post-concussion syndrome, peripheral neuropathy due to cancer
and diabetes, and neurological and orthopedic conditions.
The SMART Balance Master utilizes a dynamic force plate with rotation
capabilities to measure center of gravity position and postural control.
Additionally, it uses a dynamic visual surround to measure the patient’s
use of visual information to maintain balance. It provides assessment
and retraining capabilities with visual biofeedback on either a stable or
unstable support surface and in a stable or dynamic visual environment.
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Transforming care and creating a stronger community

Aurora Health Care is committed to making sure that all patients,
regardless of income, have access to the best care possible. That includes
health care for the un- and underinsured, services for survivors of sexual
and domestic violence, substance abuse treatment, and other supportive
services for some of the most vulnerable people in our community.
Donors to Aurora have the ability to have a major impact on these same
issues through the programs Aurora provides, spanning the organization’s
service area and serving tens of thousands of people each year.
Donor support also helps Aurora access the latest technologies and
research to improve patient outcomes and enhance the quality of care
we provide. Your gifts help to advance clinical trials, foster investigatorinitiated research, and promote medical education and awareness through
publications that reach more than 100 countries all over the world.
At Aurora Health Care Foundation, we believe that together, we have
the power to transform care and create a stronger community.

VINCE LOMBARDI CANCER FOUNDATION

VLCF Gift Spurs Neuro-Oncology Research
Last year, in honor of its 45th Anniversary, the Vince Lombardi Cancer
Foundation presented Aurora Health Care with the largest annual gift
in its history, totaling over $2 million. $1 million of that gift was set aside
for the Neuro Anatomy Lab to research and develop new therapies for
brain cancer patients.
Dr. Richard Rovin, the director of clinical research at the Aurora
Neuroscience Innovation Institute, also received an Aurora Research
Institute Cancer Research Award. Dr. Rovin is studying the best way
to isolate cancer stem cells from metastatic brain tumors to better
understand why tumors spread to the brain, aiding in cancer
prevention and the development of new treatment options.

Over the past year, Aurora Neurosciences has put that $1 million
gift to good use, hiring a senior research scientist, a technologist
and a post-doctoral fellow. The Aurora Research Institute also opened
a new laboratory facility and vivarium (animal facility) at Aurora Sinai
Medical Center.

“This gift is … a reflection of the investment the
Foundation is making in the major advancements
happening in cancer care and research at Aurora Health
Care across the state.”
— Erin Hareng, Executive Director, Vince
Lombardi Cancer Foundation

Research is currently focused on characterizing tumor stem cells. Since
tumor stem cells are the cause of recurrence and therapy resistance in
patients, this research is essential for studying new cancer therapies.
Characterization of the cells includes multimodality imaging technique,
such as Magnetic Resonance Imaging (MRI), Ramen Spectroscopy (RS)
and Optical Coherence Tomography (OCT). These imaging modalities
help identify differences between healthy and unhealthy tissue at
molecular and structural levels.

Thank you Vince Lombardi
Cancer Foundation for your
commitment to raising funds
for leading-edge cancer research
and compassionate care at
Aurora Cancer Care. We are
proud to be on your team!
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Helping people live well through innovative research

Research specialists at Aurora Research Institute are committed to
conducting cutting-edge bench and clinical research, integrating
this knowledge at the patient’s bedside and communicating valuable
patient-centered results to the community. Beneficial patientcentered outcomes are the focus of medical research at Aurora
Health Care.
There are two primary areas of patient-centered research throughout
Aurora: investigator-initiated research and clinical trials. Investigatorinitiated research includes projects and programs that Aurora
physicians and scientists develop within their special interest areas.
Clinical trials are industry- and government-sponsored projects that
provide opportunities to present new treatments to the community.
To foster investigator-initiated research, the institute offers multiple
services, including protocol design and review, regulatory submissions,
research contracting and agreements, study coordination, data
collection and statistical analysis. The Sponsored Programs Office
offers pre-award project planning and development and postaward management.
Aurora researchers conduct patient-centered research studies in the
areas of cardiovascular disease, oncology, neurosciences, and women’s
health care, among others. In 2015, Aurora Research Institute was
actively involved in 296 clinical trials with 81 full-time dedicated
employees. The health care system incorporates cutting-edge research
and evidence-based best practice into high-quality patient care.
With hundreds of active clinical trials and investigator-initiated study

protocols at any given time, Aurora patients can choose to participate
in a variety of studies, including those focused on treatments, prevention,
diagnostics, screening and quality of life.
Both research areas are supported by specialized research centers,
which allow physicians and scientists to focus on core areas and
provide the best patient-centered outcomes. Medical residents and
fellows also have the opportunity to learn from leading physicians
and scientists. Aurora also offers researchers informatics support
through novel data-mining techniques, which is viewed as an integral
part of Aurora’s ability to take advantage of its resources to enhance
provider clinical quality, individualize treatments and improve
financial performance. In addition, Aurora investigators have access
to the organization’s Institutional Review Board to ensure compliance
with all applicable human subjects protection guidelines.
Neuroscience is not only a service line where incredible treatment
happens, but also where continual research and education occur.
The neurosciences team is committed to making the latest diagnostic
and treatment options available, as well as sharing new discoveries every
day. We educate surgeons from abroad, teaching them about the
advanced technologies that have become an integral part of the
treatment for neurological disorders. In its short existence, ANII has
hosted over a hundred surgeons and allied health providers to facilitate
learning in addition to starting a cranial fellowship program. We know
our medical advancements today will help countless patients in the
future, and in neuroscience institutes around the world.
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REGENERATIVE MEDICINE CENTER
Regenerative medicine represents a form of medicine that accelerates
the body’s own healing process to generate new tissue and fully restore
the health of damaged tissues and organs. Stem cells, genes and
engineered cells/tissue are some of the tools used, sometimes in
combination with drugs or devices, to improve function and quality of
life with a minimally invasive approach. The Regenerative Medicine
Center is building on more than 20 years of experience in cellular
therapy for patients with cancer to research and develop innovative,
regenerative therapies to improve outcomes in patients with
cardiovascular and neurological disease.
Through the Regenerative Medicine Center, a pipeline has recently been
initiated where patients who are undergoing surgery to remove brain
cancer can consent to donate their tissue samples to establish a bank
for tumor cells and tumor stem cells in our Biorepository and Specimen
Resource Center. The establishment of the bank is an instrumental
resource of high-quality cells and linked medical data for local research
and academic communities within and beyond Aurora Health Care,
industry partners, and pharmaceutical companies. Ultimately, the
generation of a brain tumor stem cell bank has established an
infrastructure that is needed to further understand these cells, which
is critical to developing personalized treatment for patients with
glioblastoma and other tumors.
A related project is the research and development of new therapeutic,
targeted viral vectors for patients with brain cancer. These viral vectors
are specifically targeted to the brain tumor stem cells. Preliminary data
has shown that cell-based treatment can produce an 80% control rate
for growth of primary brain cancer in mouse models. It is expected
that this cell-based treatment will have similar therapeutic benefit in
patients with brain cancer.
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Ongoing support for the Regenerative Medicine Center includes an
initial core group of scientists and supplies for pilot experiments as
well as developments to provide multiple technical modalities and
expertise to move this potential new therapy from the laboratory
into the clinic:
• Imaging equipment to study the characteristics of tumor surfaces
and differences between normal, healthy tissue and tumor tissue
• Imaging equipment to study development of brain cancer in animal
models and to determine the efficacy of the viral vector therapy
• Image analysis software to visualize the tumor and compare and
contrast images
• Supplies to conduct the preclinical experiments in animal models
and in the laboratory
• Experts in tissue imaging and analysis to conduct these experiments
• Experts in xenotransplantation (growth of human tumor tissue
in animal models)

CLINICAL TRIALS
Innovation through clinical trials at Aurora Health Care provides the
latest techniques and technologies to our patients before they’re
available anywhere else. Clinical research is vital to advancements in
the field of health care. Research is the cornerstone for investigating
disease prevention, treatment using drugs or medical devices and
other interventions. Aurora currently has more than 300 active clinical
trials. Approximately 60 percent of these trials are focused on oncology,
25 percent on cardiovascular and the remaining 15 percent consist of
neurology, gastroenterology, orthopedics and women’s health.
Aurora patients can participate in several types of clinical
trials including the following:
•S
 creening/prevention trials: Seeking methods of early
detection or prevention of disease and looking for better
ways to prevent reoccurrence.
•D
 iagnostic trials: Finding better tests or procedures for diagnosing
a particular disease or condition.
 reatment trials: Testing new therapies (drugs and/or devices),
•T
combinations of drugs and/or devices)or approaches to
medical procedures.
 uality of life trials: Exploring ways to improve comfort and the
•Q
quality of life for individuals with a chronic illness.
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High standards for Aurora’s clinical research trials
Aurora’s research staff collaborates with many highly-respected
universities in Wisconsin and throughout the nation. Researchers work
closely with the National Institutes of Health, the U.S. Agency for
Research and Health Care Quality, as well as the U.S. Department of
Health and Human Services. Aurora also has participated in many
multicenter clinical trial programs, working to answer questions
posed by other doctors and scientists and contributing data to the
approval of new drugs and devices.
Every clinical trial at Aurora is conducted according to the highest
ethical and professional standards to ensure the protection of the
individuals who volunteer to participate. Aurora is proud to be one
of the first medical organizations to have a research subject protection
program accredited by the Association for Accreditation of Human
Research Protection Program.

DISCOVERY LAB
In Aurora Research Institute’s Discovery Laboratory, scientists
work from the molecular to cellular levels to find innovative ways
to improve care and patient outcomes for cancer, cardiovascular
diseases, neurological disorders and other special focus areas.
The space-saving layout of the Discovery Laboratory features shared
work stations and communal core equipment. This efficient design
avoids duplication found in traditional pod-like laboratories and
enhances communication among researchers. The tissue processing
and microscopy area is equipped for preparation, staining and analysis
of slides. Typically this service is outsourced, adding cost and time
to research projects. An enclosed area at biosafety level 2 allows for
genetic manipulation using viruses and other microorganisms to

develop new immunotherapies. A refrigerated room allows for
cold-temperature experiments. A separate room houses deep-freeze
cryogenic equipment for storage of tissues, cells and supplies at -20,
-80 and -150 degrees. Rounding out the laboratory are traditional
human and animal cell and tissue preparation and culture spaces.

Discovery Laboratory features include:
• Imaging Laboratory with some equipment not found anywhere
else in the world
• Experimental Optics Laboratory
• Microscopy/Histology Laboratory
• Cell Biology Laboratory
• Flow Cytometry Laboratory
• Virology Laboratory
• Protein and Molecular Laboratory
Aurora Research Institute’s Discovery Laboratory has the tools
and technologies to make an impact in special focus areas of
neuroscience, which include the following:
•V
 iral vectors: Determining whether genetic material delivered
into cancer stem cells reduces the rate of tumor growth.
 alignant gliomas: Developing cellular therapies and ways to
•M
diagnose this common and aggressive brain tumor earlier.
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As part of the research protocol, subjects are randomized to receive
the chemotherapy and PARP inhibitor or the chemotherapy and
placebo sugar pill. Zellmer agreed to enroll in the trial, even
though she couldn’t be sure she would receive the PARP inhibitor.
“If it could extend my life, why not?” Zellmer said.

Support and care
A spiritual person, Zellmer has relied on her Christian faith, positivity and
extensive support system to carry her through. Not only has her immediate
family—husband, John and sons, Zachary, 22, Benjamin, 10, and Aaron, 8—
stepped up, but her mother and sister in Washington, her brother in Alaska
and friends and neighbors—“people we didn’t even know”—are pitching in.

Surrounded by beauty
The family’s vacation to Hawaii, originally planned for Christmas,
transformed into Zellmer’s 50th birthday celebration in February.
Though she didn’t want to feel ill from the therapy during the trip,
she didn’t want it looming over her head either. She started the first
round of the study treatment, an oral therapy, in Hawaii.
“It was still worth it,” Zellmer said. “Being in Hawaii, being outside
surrounded by beauty, was very good for my well-being.”
Feeling ill the first two days, she checked in with research study
coordinator Lynda Yanny, BSN, who told her how to “stay ahead”
of the symptoms.
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And she couldn’t say enough about her care team throughout Aurora
Health Care. “I feel like I’m getting the best care I can get,” she said.
Looking forward
Zellmer takes one day at a time. She’s looking forward to seeing Zachary
graduate college in Seattle this June. Study treatments wrap up, though
she will be followed for 10 years.
“I think medicine has changed a lot,” Zellmer said. “I’m thankful it is the
decade we live in now and hope there are more studies to cure this.
Walking a mile a day, Zellmer hopes to hike the bluffs of Devil’s Lake
again this fall. She goes for an MRI every eight weeks to see if the tumor
has grown back. Her scan in March was clear of tumors.
Zellmer is participating in a trial being conducted by Alliance for Clinical Trials in Oncology.
Alliance is a member of the National Cancer Institute National Clinical Trials Network and serves
as a research base for the NCI Community Research Oncology Program. Aurora St. Luke’s
Medical Center is member of the Alliance NCTN network. Zellmer’s experience should not be
used to predict outcomes of the clinical trial. Data collection continues.

A depiction of how veliparib works in the fight against cancer.
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Researchers kick-start neurooncology research program
with funds from Vince Lombardi
Cancer Foundation
With a generous $1 million grant from Vince Lombardi Cancer
Foundation, vice president of Aurora Neurosciences Amin
Kassam, MD, is leading the development of a neuro-oncology
research program.

Stem cell bank
Access to human brain tumor samples is essential for a successful
neuro-oncology research program to thrive, since the stem cells
derived from the samples will be used to test new cancer therapies
in the lab.
With an initial Aurora Cancer Care Research Award in 2014 and
continued funding in 2015—totaling $50,000—Kassam established
a brain tumor stem cell bank. The research award program is
generously supported by Vince Lombardi Cancer Foundation.
Using residual tissue from surgeries to remove brain tumors,
researchers are collecting samples to grow and store stem cells.
The project was initiated in an existing laboratory in the Regenerative
Medicine Center at Aurora St. Luke’s Medical Center. The proximity
of the lab to the operating rooms was advantageous to facilitate
effective communication between the study team, operating room
staff and pathology, as well as efficient transfer of the tumor tissue
from the operating room to the lab.
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Coordination and streamlining of the process required the
collaboration of neurosciences research nurse coordinators,
representatives of the Biorepository and Specimen Resource
Center, researcher scientists and technologists, and the surgeons.
Researchers collected 76 samples of a variety of brain tumors
from 60 patients. The research team developed a novel method
to culture the tumor stem cells with an exceptional success rate.
Tissue collection is ongoing.

Researchers collected 76 samples of a variety of
brain tumors. Using a novel culture method, the
team has demonstrated exceptional success rates.

Clinical trial
spotlight
Researchers track outcomes of new
multiple sclerosis drug
Recurring attacks, or relapses, of neurological
symptoms are common in multiple sclerosis.
The drug dimethyl fumarate cuts down on the
number of relapses.
James Napier, MD, is leading an observational
clinical trial at Aurora BayCare Medical Center
to track serious adverse events that lead to the
discontinuation of dimethyl fumarate in patients
with relapsing multiple sclerosis (ESTEEM,
clinicaltrials.gov identifier: NCT02047097).

The drug dimethyl fumarate
cuts down on the number
of relapses.
Sponsored by the drug’s manufacturer, Biogen Inc.,
the global study will follow about 5,000 subjects
for five years. Researchers will track different
serious adverse events, including infections,
hepatic events, malignancies and renal events.
Jennifer Homa, MS, is serving as site coordinator.

Targeted treatment

NEURO RESEARCH COMMITTEES

Testing new precision
cancer therapies

Neurosciences Research Committee

Developing new strategies to treat
the most frequent forms of brain
cancer is the driving force behind
the research of senior research
scientist Santhi Konduri, Ph.D.,
and neuro-oncologist George
Bobustuc, MD.
Patient-derived cancer cells are
tested to identify different markers
associated with glioblastoma
multiforme and meningioma brain
cancers. The long-term goal is to
understand molecular changes that
occur during tumor development and
to use these molecular markers as
therapeutic targets, individualizing
treatment to the patient’s specific
genetic make-up.
The ultimate goal is to design a safe,
effective system allowing for use of
a combination of drugs and therapies
unique to each patient.
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